Mifamurtide (sodium hydrate)

• UNSPSC Description:

  Mifamurtide (sodium hydrate) (MTP-PE (sodium hydrate); L-MTP-PE (sodium hydrate); CGP 19835 (sodium hydrate)) is the sodium hydrate of mifamurtide. Mifamurtide is a nonspecific immunomodulator that acts by stimulating immune responses by activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and is used as an insulin sensitizer and may also be used in osteosarcoma research[1][2][3].

• Target Antigen:

  Others

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/mifamurtide-sodium-hydrate.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CCCCCCCCCCCCCCCC(OC[C@@H](OC(CCCCCCCCCCCCCCC)=O)COP(OCCNC([C@@H](NC(CC[C@@H](NC([C@@H](NC([C@H](O[C@]([C@H](O)[C@H](O)CO)([H])[C@@H](NC(C)=O)C=O)C)=O)C)=O)C(N)=O)=O)C)=O)(O[Na])=O)=O.[H]O[H].[x]

• References & Citations:

  [1]Kevin Biteau, et al. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. Am J Cancer Res. 2016 Feb 15;6(3):677-89.|[2]Joseph F Cavallari, et al. Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell Metab. 2017 May 2;25(5):1063-1074.e3.|[3]Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D, 2008. 9(2): p. 131-5.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  838853-48-8